Adipose-Derived Cellular Stromal Vascular Fraction for Post-COVID 19 Survivors

Scientific Study: Overview of COVID-19 Lung Damage Clinical Trial Using Cellular Stromal Vascular Fraction (cSVF) and Functional Respiratory Imaging (FRI) Analysis of Pulmonary Injury & Post-Viral (SARS- CoV-2) Adult Respiratory Distress Syndrome (ARDS)

SDARTs faculty member, Robert W. Alexander, MD, DDS, is the Principle Investigator on a first-in-human clinical trial using AD cSVF to treat post-COVID 19 survivors suffering residual lung damage.

Many moderate to severe post-COVID 19 survivors experience compromised lung function. As a proposed solution, adipose-derived cellular stromal vascular fraction (AD cSVF) may be effective in reversing residual damage to the lungs and gas exchange functions.

This study was published in Stem Cell Research.